Matthew C Mulvey

age ~49

from Gaithersburg, MD

Get Report

Also known as:

Connected to:

Matthew Mulvey Phones & Addresses

Virulent Oncolytic Herpes Simplex Virus Strains Engineered To Counter The Innate Host Response
view source
US Patent:

8252277, Aug 28, 2012
Filed:

Apr 27, 2010
Appl. No.:

12/767973
Inventors:

Ian Mohr - New York NY, US
Matthew Mulvey - New York NY, US
Assignee:

New York University - New York NY
International Classification:

A61K 48/00
A61K 39/00
US Classification:

424 932, 4242291
Abstract:

The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ34. 5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.

Avirulent Oncolytic Herpes Simplex Virus Strains Engineered To Counter The Innate Host Response
view source
US Patent:

20060039894, Feb 23, 2006
Filed:

Jun 24, 2005
Appl. No.:

11/166438
Inventors:

Ian Mohr - New York NY, US
Matthew Mulvey - New York NY, US
International Classification:

C12N 7/00
A61K 35/76
US Classification:

424093600, 435235100
Abstract:

The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ34.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.

Avirulent Oncolytic Herpes Simplex Virus Strains Engineered To Counter The Innate Host Response
view source
US Patent:

20130034586, Feb 7, 2013
Filed:

Jul 30, 2012
Appl. No.:

13/561823
Inventors:

Ian Mohr - New York NY, US
Matthew Mulvey - New York NY, US
Assignee:

NEW YORK UNIVERSITY - NEW YORK NY
International Classification:

A61K 35/76
C12N 7/04
A61P 37/00
A61P 35/00
A61P 31/00
US Classification:

4242311, 435236
Abstract:

The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ34.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.

Oncolytic Herpes Simplex Virus And Therapeutic Uses Thereof
view source
US Patent:

20150110822, Apr 23, 2015
Filed:

Sep 7, 2012
Appl. No.:

14/343108
Inventors:

Ian J. Mohr - New York NY, US
Matthew C. Mulvey - Baltimore MD, US
Assignee:

BENEVIR BIOPHARM, INC. - Baltimore MD
NEW YORK UNIVERSITY - New York NY
International Classification:

A61K 35/763
C12N 15/86
C12N 7/00
US Classification:

4241861, 4353201
Abstract:

The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, e.g., for treating cancer in a subject, are also provided.